WO2023199893A1 - 活性型オレキシンａを定量する方法 - Google Patents

活性型オレキシンａを定量する方法 Download PDF

Info

Publication number
WO2023199893A1
WO2023199893A1 PCT/JP2023/014583 JP2023014583W WO2023199893A1 WO 2023199893 A1 WO2023199893 A1 WO 2023199893A1 JP 2023014583 W JP2023014583 W JP 2023014583W WO 2023199893 A1 WO2023199893 A1 WO 2023199893A1
Authority
WO
WIPO (PCT)
Prior art keywords
orexin
disease
active
peptide
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2023/014583
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
勘太 堀江
和浩 田原
英美子 湯本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Priority to CN202380026755.6A priority Critical patent/CN118984938A/zh
Priority to EP23788311.1A priority patent/EP4478051A4/en
Priority to US18/845,692 priority patent/US20250189543A1/en
Priority to JP2024514957A priority patent/JPWO2023199893A1/ja
Publication of WO2023199893A1 publication Critical patent/WO2023199893A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Definitions

  • a method for quantifying active orexin A includes a step of contacting a sample with a monoclonal antibody that recognizes the C-terminal side of orexin A to separate orexin A species; The method includes a step of digesting the seed with protease to obtain a peptide consisting of the amino acid sequence represented by SEQ ID NO: 1, and a step of subjecting the peptide to mass spectrometry.
  • Orexin A species is a general term for intact orexin A that has not undergone metabolism and metabolites of orexin A.
  • FIG. 6 is a graph showing the amount of active orexin A (vertical axis) measured by the method of Example 3 in the cerebrospinal fluid of five subjects.
  • Auth-OXA refers to long orexin A (active orexin A) including the N-terminus
  • IPMS refers to the method for quantifying active orexin A according to the present disclosure.
  • FIG. 7 is a graph showing the amount of orexin A (total amount of N-terminal orexin fragments containing active orexin A) (vertical axis) measured by chemiluminescence-EIA method in Comparative Example 4.
  • FIG. 6 is a graph showing the amount of active orexin A (vertical axis) measured by the method of Example 3 in the cerebrospinal fluid of five subjects.
  • Auth-OXA refers to long orexin A (active orexin A) including the N-terminus
  • IPMS refers to the method for quantifying active orexin A according to the present disclosure.
  • OXA refers to orexin A
  • chemilumi-EIA refers to chemiluminescence-EIA method.
  • the values on the vertical axis are relative values (%) when the average of the measured values for each individual is taken as 100%.
  • a fitting curve calculated with reference to Psychiatry 2003, 54, 96-104 is also shown.
  • the horizontal axes in FIGS. 6 and 7 indicate time. ID1 to ID5 in FIGS. 6 and 7 refer to each of the five subjects.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
PCT/JP2023/014583 2022-04-11 2023-04-10 活性型オレキシンａを定量する方法 Ceased WO2023199893A1 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN202380026755.6A CN118984938A (zh) 2022-04-11 2023-04-10 对活性型食欲素a进行定量的方法
EP23788311.1A EP4478051A4 (en) 2022-04-11 2023-04-10 METHOD FOR QUANTIFYING ACTIVE OREXIN A
US18/845,692 US20250189543A1 (en) 2022-04-11 2023-04-10 Method for quantifying active orexin a
JP2024514957A JPWO2023199893A1 (https=) 2022-04-11 2023-04-10

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2022065117 2022-04-11
JP2022-065117 2022-04-11

Publications (1)

Publication Number Publication Date
WO2023199893A1 true WO2023199893A1 (ja) 2023-10-19

Family

ID=88329773

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2023/014583 Ceased WO2023199893A1 (ja) 2022-04-11 2023-04-10 活性型オレキシンａを定量する方法

Country Status (5)

Country Link
US (1) US20250189543A1 (https=)
EP (1) EP4478051A4 (https=)
JP (1) JPWO2023199893A1 (https=)
CN (1) CN118984938A (https=)
WO (1) WO2023199893A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025137359A1 (en) * 2023-12-20 2025-06-26 Eisai R&D Management Co., Ltd. Assay methods to identify a disease
WO2025183053A1 (ja) * 2024-02-29 2025-09-04 株式会社島津製作所 生体液中のタウタンパク質の翻訳後修飾および／または断片化の質量分析法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000516456A (ja) * 1996-08-02 2000-12-12 ザ・スクリプス・リサーチ・インステイチユート 視床下部特異的ポリペプチド

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000787A2 (en) * 1999-06-25 2001-01-04 Smithkline Beecham Corporation Methods of treatment using lig 72a and variants thereof
JP3935487B2 (ja) * 2001-07-16 2007-06-20 フーベルト・ケスター 捕獲化合物、その収集物、ならびにプロテオームおよび複合組成物の分析方法
WO2018078018A2 (en) * 2016-10-27 2018-05-03 Glostrup Hospital Detection of hypocretin-1 and -2

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000516456A (ja) * 1996-08-02 2000-12-12 ザ・スクリプス・リサーチ・インステイチユート 視床下部特異的ポリペプチド

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CHROBOK LUKASZ, BAJKACZ SYLWIA, KLICH JASMIN DANIELA, LEWANDOWSKI MARIAN HENRYK: "LC-MS/MS Analysis Elucidates a Daily Rhythm in Orexin A Concentration in the Rat Vitreous Body", MOLECULES, vol. 26, no. 16, 19 August 2021 (2021-08-19), pages 5036, XP093099538, DOI: 10.3390/molecules26165036 *
LANG MANJA, SÖLL RICHARD M., DÜRRENBERGER FRANZ, DAUTZENBERG FRANK M., BECK-SICKINGER ANNETTE G.: "Structure−Activity Studies of Orexin A and Orexin B at the Human Orexin 1 and Orexin 2 Receptors Led to Orexin 2 Receptor Selective and Orexin 1 Receptor Preferring Ligands", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 47, no. 5, 1 February 2004 (2004-02-01), US , pages 1153 - 1160, XP055980754, ISSN: 0022-2623, DOI: 10.1021/jm030982t *
LINDSTRÖM MIKAEL; SCHINKELSHOEK MINK; TIENARI PENTTI J.; KUKKONEN JYRKI P.; RENKONEN RISTO; FRONCZEK ROLF; LAMMERS GERT JAN; ITKON: "Orexin-A measurement in narcolepsy: A stability study and a comparison of LC-MS/MS and immunoassays", CLINICAL BIOCHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 90, 1 February 2021 (2021-02-01), AMSTERDAM, NL, pages 34 - 39, XP086517302, ISSN: 0009-9120, DOI: 10.1016/j.clinbiochem.2021.01.009 *
MANJA, L ET AL.: "Structure-Activity Studies of Orexin A and Orexin B at the Human Orexin 1 and Orexin 2 Receptors Led to Orexin 2 Receptor Selective and Orexin 1 Receptor Preferring Ligands", J. MED. CHEM., vol. 47, no. 5, 2004, pages 1153 - 1160, XP055980754, DOI: 10.1021/jm030982t
MIRIAM, W. ET AL.: "Progressive dopamine and hypocretin deficiencies in Parkinson's disease: Is there an impact on sleet and wakefulness?", J SLEEP RES, vol. 21, no. 6, December 2012 (2012-12-01), pages 710 - 717
ONO TAISUKE, TAKASHI KANBAYASHI, KAZUHISA YOSHIZAWA, SEIJI NISHINO, TETSUO SHIMIZU: "Measurement of cerebrospinal fluid orexin-A (hypocretin-1) by enzymelinked immunosorbent assay: A comparison with radioimmunoassay,", PSYCHIATRY AND CLINICAL NEUROSCIENCES, BLACKWELL SCIENCE, CARLTON, AU, vol. 72, no. 11, 1 November 2018 (2018-11-01), AU , pages 849 - 850, XP093099540, ISSN: 1323-1316, DOI: 10.1111/pcn.12780 *
SAKAI, N.MATSUMURA, M.LIN, L. ET AL.: "HPLC analysis of CSF hypocretin-1 in type 1 and 2 narcolepsy", SCIENTIFIC REPORTS, vol. 9, 2019, pages 477
SALOMON, RM ET AL., BIOL. PSYCHIATRY, vol. 54, 2003, pages 96 - 104
See also references of EP4478051A4

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025137359A1 (en) * 2023-12-20 2025-06-26 Eisai R&D Management Co., Ltd. Assay methods to identify a disease
WO2025183053A1 (ja) * 2024-02-29 2025-09-04 株式会社島津製作所 生体液中のタウタンパク質の翻訳後修飾および／または断片化の質量分析法

Also Published As

Publication number Publication date
EP4478051A1 (en) 2024-12-18
EP4478051A4 (en) 2026-01-21
CN118984938A (zh) 2024-11-19
JPWO2023199893A1 (https=) 2023-10-19
US20250189543A1 (en) 2025-06-12

Similar Documents

Publication Publication Date Title
WO2023199893A1 (ja) 活性型オレキシンａを定量する方法
KR101559101B1 (ko) 혈액유래 암 진단용 펩티드 마커 및 이를 이용한 암 진단방법
AU2010204066B2 (en) Method for detecting all Haemophilus influenzae
CN117624357B (zh) p-Tau 217特异性抗体及其在阿尔茨海默症辅助诊断试剂盒的应用
JP2025098086A (ja) 血液試料を検体とするタウタンパク質検出方法
JP6074846B2 (ja) 髄液型糖タンパク質の富化及び分離方法、並びにその方法を用いた中枢神経系疾患用マーカーの探索方法及び中枢神経系疾患用マーカー
JP7229592B2 (ja) 抗原の組み合わせ、アルツハイマー病の検出への抗原の組み合わせの使用、アルツハイマー病を検出するキット及びアルツハイマー病の検出用抗原
JP2022177100A (ja) 未発症の『危険相』から関節リウマチ、ＡＡＶ、又はシェーグレン症候群への遷移のバイオマーカーとしてのＦａｂ結合型糖鎖
CN116754772B (zh) 老年痴呆早期诊断外周血蛋白标志物、应用及辅助诊断系统
CN118955709B (zh) 217位磷酸化pTau217蛋白单克隆抗体及其应用
CN108026522B (zh) 特异性纯化的抗普莱晒谱星抗体
CN111505315A (zh) 一种蛋白组合式标志物在制备儿童哮喘诊断试剂中的应用
CN108957013B (zh) 与骨关节炎相关的iglon5和serpinb13蛋白及其应用
CN109810184B (zh) 人nf155抗原、人nf155抗体检测试剂盒及其制备方法与应用
JP2022527087A (ja) タウオパチーを診断するためのｐＳ３９６アッセイの使用
CN115494241B (zh) 脑脊液中蛋白标志物在制备诊断轻度认知功能损害的产品中的应用
JP2016114573A (ja) オキシトシン検出のためのサンプルの前処理方法
EP3177312B1 (en) Method and kit for detecting bacterial infection
EP2731968A1 (en) Monoclonal antibodies specific for beta-amyloid x-37 and uses thereof
CN117820472B (zh) p-Tau 181特异性抗体及其在阿尔茨海默症辅助诊断试剂盒的应用
JP7475584B2 (ja) 免疫グロブリンａに結合しているペリオスチン並びに免疫グロブリンａに結合しているペリオスチンに結合する抗体、ペリオスチンの測定方法、ペリオスチンの測定試薬及びペリオスチン測定の正確性の改善方法
WO1994010205A1 (fr) Proteine specifique de la maladie d'alzheimer et procede de diagnostic de cette maladie par detection de ladite proteine
WO2024047185A1 (en) Mass spectroscopy assay for detecting o-beta-linked n-acetylglucosaminylated tau peptides
CN107796946B (zh) 尿液中冠心病的蛋白标志物及其用途
CN119350504A (zh) 一种蛋白质半胱氨酸羧乙基化修饰检测的方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23788311

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2024514957

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 18845692

Country of ref document: US

Ref document number: 202380026755.6

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2023788311

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2023788311

Country of ref document: EP

Effective date: 20240911

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 18845692

Country of ref document: US